Jesta Group is a proud investor in cResponse, an innovative cancer treatment technology designed by Curesponse in collaboration with the Weizmann Institute of Science, in order to provide a more personalized and efficient treatment of the disease.

cResponse takes a unique approach to evaluate each patient’s specific response to multiple cancer drugs. Its proprietary evaluation system & response algorithm allows to identify the optimal treatment while preventing the unnecessary use of ineffective drugs.

After strong validation in pre-clinical trials, cResponse is undergoing validation in human clinical trials showing promising results for a wide range of cancers.